Reprogramming T Cells to Defeat Solid Tumors

Our Story
hero image
Rick Klausner, M.D.,Founder & Board Chair

Founder's Vision

Lyell Founder and Board Chair Rick Klausner, M.D., shares his vision for conquering oncology’s unfinished business – curative cell therapy for solid tumors.

Our Science icon

Our Science

Technologies designed to address major barriers to effective cell therapy in solid tumors.

Our Pipeline icon

Our Pipeline

Our multi-modal product pipeline targets solid tumor cancers with significant unmet medical need.

Dedicated to Patients

An unwavering focus on science guides our mission to deliver transformative T-cell therapies that can go the distance for patients with solid tumors.

Learn More
Latest News

Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of Melanoma

SOUTH SAN FRANCISCO, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today announced that the U.S.

View All News

Join Our Team

At Lyell, we are driven by our mission and focused on developing transformative therapies to improve the lives of patients.

Join our team of ambitious Lyellites who are committed to defeating solid tumor cancers through innovation.

See Open Positions